Your session is about to expire
← Back to Search
EO2040 + Nivolumab for Colorectal Cancer (CLAUDE Trial)
CLAUDE Trial Summary
This trialwill test a vaccine and an immunotherapy drug to see if they can reduce colorectal cancer after standard treatments.
CLAUDE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCLAUDE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 541 Patients • NCT02041533CLAUDE Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have traces of cancer detected by a blood test after finishing all standard treatments.I am not on any immune-affecting drugs or herbal remedies that could harm my organs.I haven't had any live vaccines, including the flu shot, in the last 4 weeks.I am HLA-A2 positive.I am willing and able to follow the study's schedule and procedures.I have a history or current case of HIV, HBV, or HCV.I have a history or current diagnosis of tuberculosis.I haven't had radiotherapy in the last 12 weeks or chemotherapy in the last 28 days.You have had an organ transplant or a type of stem cell transplant from another person.I haven't had treatments targeting PD1, PD-L1, CTLA-4, or similar.I am allergic to certain medications or their ingredients.I've had surgery to remove my stage II-IV colorectal cancer and completed all standard treatments.My side effects from previous treatments are mild and have been stable for at least 2 weeks.My colorectal cancer has been confirmed through a biopsy.I am 18 years old or older.I am a woman who can have children and have a recent negative pregnancy test.I am taking more than 2 mg/day of dexamethasone or its equivalent.You cannot have received any experimental treatments or participated in another clinical trial.I have another active cancer besides the one being treated.I have or might have an autoimmune disorder, including conditions like Guillain-Barré syndrome.
- Group 1: Patients With Minimal Residual Disease of Colorectal Cancer
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any open enrolment slots for this clinical experiment?
"Affirmative. In accordance with clinicaltrials.gov, this medical trial initiated on March 1st 2023 is currently recruiting participants. There are 34 spots available at a single site to be filled by the end of January 26th 2023."
How many participants can the clinical trial accommodate?
"Affirmative. According to the information published on clinicaltrials.gov, this study is presently recruiting participants. It was initially posted in March 1st of 2023 and recently updated by January 26th of the same year. 34 individuals are needed from a single site for the trial's completion."
Has the FDA sanctioned Patients With Minimal Residual Disease of Colorectal Cancer?
"There is some evidence indicating the safety of this treatment for patients with minimal residual disease of colorectal cancer, resulting in a score of 2. However, there are no studies that have been conducted to verify its efficacy."
Share this study with friends
Copy Link
Messenger